CClinicalTrials.gg
RecruitingNCT05752448POSTCARE-OUpdated Apr 3, 2026

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)

An interventional study of POSTCare Survivorship transition process in Ovarian Neoplasm, Depressive Symptoms and Quality of Life, sponsored by Baylor College of Medicine. Recruiting at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study will enroll 120 women living with ovarian cancer following completion of initial treatment. Our objective is to test an intervention designed to provide support during the survivorship transition for this population, who live with a high degree of morbidity related to the illness and its treatment as well as a high risk of recurrence. Study participants will be randomly assigned to receive survivorship care using the POSTCare-O process or usual care. The primary outcome is quality of life at 12 weeks after intervention.

Read the detailed description

Study Design We will conduct a 2-arm randomized controlled trial to evaluate the impact of a telehealth delivered survivorship transition care process. Ovarian cancer survivors (120) will be randomly allocated to receive survivorship care either using the POSTCare Process or standard of care. Study design and reporting will be in accordance with the Consolidated Standards of Reporting Trials (CONSORT) checklist. We will use quantitative and qualitative methodologies in a concurrent triangulation mixed methods design utilizing qualitative data to augment our interpretation of quantitative data. Outcomes will be collected at baseline, 12 weeks and 24 weeks, with the primary outcome being quality of life assessment at 12 weeks.

Sample Size We will enroll 120 women completing primary treatment for Stage 2-4 ovarian cancer from 3 urban gynecologic oncology clinics located in the Southern United States. Participants will have received some combination of surgery, chemotherapy, radiation therapy, and biologics. Continued maintenance therapy is not an exclusion factor. Aim 1 proposes to implement a randomized controlled trial (RCT) devised to compare QOL measures among ovarian cancer patient randomized to receive usual care versus the POSTCare survivorship care transition program. The Functional Assessment of Cancer Therapy-Ovarian (FACT-O) QOL survey will be collected at baseline as well as 12 and 24 weeks after the initial course of adjuvant chemotherapy. The primary endpoint will be the 12-week survey. We expect to observe a mean 12-week FACT-O score of 116 with standard deviation of 20 for women receiving usual care. The sample size of N=120 patients provides at least 80% power to detect a 7% increase in the mean FACT-O score for women randomized to the POSTCare survivorship care intervention. This is sufficient to ascertain a minimally important difference of 8 points.

Recruitment and Setting We will recruit participants from Gynecologic Oncology practices at 3 clinic settings in Texas: One safety net practice located in Dallas, one safety net practice located in Houston, and one faculty group practice located in Houston. Cumulatively the sites serve approximately 120 eligible patients per year and ensure a diverse population can be recruited during the 24-month recruitment period. 120 women will be recruited. Sixty participants will be randomly assigned to the intervention group and receive care using the POSTCare Process and 60 will be randomly assigned to the control group. It is anticipated that our study sample will reflect the ethnic and racial diversity of our clinical settings.

02

Conditions studied

  • Ovarian Neoplasm
  • Depressive Symptoms
  • Quality of Life

Keywords

  • Ovarian Cancer
  • Survivorship
  • Cancer Survivor
  • Depression
  • Palliative Care
  • Quality of Life
03

In context

Ovarian Neoplasms

2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 734 studies on the registry; 110 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 44 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Stage 2-4 ovarian cancer
  • Treated with some combination of surgery, chemotherapy, biologics, maintenance therapy
  • Within 6 months of completion of initial treatment (continued maintenance therapy okay)
  • Able to provide consent in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Admission to hospice at the completion of treatment for ovary cancer
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Group received care Using POSTCare process

    Behavioral: POSTCare Survivorship transition process

  • No intervention
    Usual Care

    Group received usual care

Interventions

  • BehavioralPOSTCare Survivorship transition process

    Survivorship coaching intervention

06

What researchers measure

Primary outcomes

  1. Quality of Life by FACT-O

    Quality of life measured by Functional Assessment of Cancer Therapy - Ovarian instrument composite scorecomprised of physical, emotional, functional, social, and disease specific subscales. Scoring range 0 - 152; a higher score indicates better quality of life.

    Time frame: 12 Weeks

Secondary outcomes

  1. Quality of Life by FACT-O

    Quality of life measured by Functional Assessment of Cancer Therapy - Ovarian instrument composite scorecomprised of physical, emotional, functional, social, and disease specific subscales. Scoring range 0 - 152; a higher score indicates better quality of life.

    Time frame: 24 weeks

  2. Recurrence Fear

    Fear of Cancer Recurrence measured by Fear of Cancer Recurrence Inventory Short Form. Range 0-36; higher score indicates higher fear of cancer recurrence.

    Time frame: 12 and 24 weeks

  3. Depressive Symptom Burden

    Depression measured by the Patient Health Questionnaire - 9 . Range 0-27; higher score indicates greater depressive symptom burden.

    Time frame: 12 and 24 weeks

  4. Symptom Burden

    Symptom Burden measured by The M.D. Anderson Symptom Inventory. Range is 1-130; higher score indicates greater symptom burden

    Time frame: 12 and 24 weeks

07

Study locations

2 of 3 sites recruiting
  • UT Southwestern Parkland Health and Hospital System
    Dallas, Texas 75235, United States
    Not yet recruiting
  • Dan L Duncan Comprehensive Cancer Center at the O'Quinn Medical Tower at Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
    Recruiting
  • Harris Health Smith Clinic
    Houston, Texas 77054, United States
    Recruiting
08

References and documents

Publications

  • Kvale E, Phillips F, Ghosh S, Lea J, Hoppenot C, Costales A, Sunde J, Badr H, Nwogu-Onyemkpa E, Saleem N, Ward R, Balasubramanian B. Survivorship Care for Women Living With Ovarian Cancer: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2024 Feb 9;13:e48069. doi: 10.2196/48069. PubMed 38335019 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05752448
Lead sponsor
Baylor College of Medicine
Collaborators
Cancer Prevention Research Institute of Texas, The University of Texas Health Science Center, Houston, University of Texas Southwestern Medical Center, University of Texas at Austin
Responsible party
Elizabeth A Kvale (Associate Professor of Medicine, Baylor College of Medicine) — Principal investigator
First posted
Mar 2, 2023
Start date
Oct 1, 2023
Primary completion
Jul 1, 2026 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Nimrah Saleem, MPH
Contact
nsaleem@bcm.edu
713-798-2272
Judy Bettencourt, MPH
Contact
judith.l.bettencourt@uth.tmc.edu
(713) 500-9527
Elizabeth Kvale, MD,MPH
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion